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Abstract
Until today, Tuberculosis (TB) is still taking part as a world health problem, especially
in The South East Asia Region. TB in South East Asia contributes almost 50% of the
worldwide burden. Indonesia is one of the regional countries that provide to the
statistics, and the World Health Organization (WHO) enlisted it in the 30 High-TB-
Burden Countries. The high number of TB in Indonesia mostly caused by a lack of case
registration, non-adherence of treatment, and lost to follow-up. This study conducted
an overview of systematic review based on Prisma Protocol to systematically and
objectively focus on the economic burden as a risk factor of non-adherence of TB
treatment in Indonesia. Relevant literature was searched from PubMed, Science Direct,
Google Scholar and reviewed abstracts and full-text article based on eligibility criteria.
Seven studies included in this review after selected using inclusion and exclusion
criteria. The studies revealed a consistent association between economic burden as
a risk factor of non-adherence of TB treatment. In conclusion, financial burden was
significant with non-adherence of TB treatment and most of TB patient who stopped
the treatment should spare their family spending into TB treatment and this often
constitutes to more considerable financial risk for them.
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1. Introduction
One of the untreated infectious diseases that contribute to the high rate of death is
Tuberculosis (TB). TB is an infectious disease caused by Mycobacterium tuberculosis
that commonly affects the lungs. TB patients have symptoms of a phlegm cough with
blood for two weeks or more, shortness of breath, weakness, weight loss and decreased
appetite, night sweat, and fever for more than one month [1].
By 2015, a new case of TB across the world was estimated to be 10.4 million in which
Southeast Asia region contributed 46.5% (> 4.7 million) to the world’s TB case burden.
Indonesia ranks second after India, with 1.02 million new cases in 2015. Meanwhile, the
death rate from TB disease in Indonesia is 45 per 100.000 populations [2].
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One of the things that need to be aware of and most challenging in the treatment
of TB disease is the resistance of Mycobacterium tuberculosis to INH and Rifampicin
called multi-drug resistance (MDR-TB). WHO states that only 52% of MDR-TB were suc-
cessful in the treatment of TB across the world, and less than 49% were successful in the
treatment of MDR-TB in the Southeast Asia region. Globally, 250.000 people died from
TB drug resistance, and only 37% of MDR-TB cases were detected. The MDR-TB case
in Indonesia was 32.000 in 2015 and the ranked second in Southeast Asia. As many as
71% of MDR-TB was confirmed and did follow the treatment, while the rest refused the
treatment or died. Meanwhile, only 51% of MDR-TB patients had a successful result in a
treatment program [2].
Results of Riset Kesehatan Dasar (Riskesdas) Year 2013 illustrate that the magnitude
of TB problems between groups in each characteristic shows differences. In the age
group, the highest prevalence is in the 65-74-year age group. Unemployed TB patients
were the greatest prevalence when compared with TB patients who worked as employ-
ees, entrepreneurs, farmers/fishers/laborers, and others. In the education group, the
highest incidence of TB patients is in the non-school education group, and as the level
of education goes higher, the prevalence goes lower [1].
Increases in TB cases are thought to be caused by various causes, such as improper
diagnosis, inadequate treatment, HIV endemic infections, population migration, self-
medication, increased poverty, and insufficient health services [3]. WHO states in Adi-
tama [4] that non-adherence to TB treatment that may lead to treatment failure caused by
the degree of poverty of the sufferer, difficulties in reaching health facilities, lack health
workers, expensive drug prices, and convoluted procedures. TB ensues in poverty and
creates poverty; in fact, the poor will have a five-time higher chance of getting TB.
Some barriers to TB control in South East Asia Region include failure to address poverty,
undernutrition and risk factors that will become exposure to TB [2].
Non-adherence with TB treatment provided by the government becomes one of the
challenges in implementing TB treatment programs in Indonesia. Non-adherence of
treatment by TB patients may be affected by many things. This review will focus on the




This study is a systematic review of the literature on the economic burden and non-
adherence TB treatment in Indonesia. Study results reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA). An
outline of the evidence searches and study inclusion provided as shown in Figure 1.
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Figure 1: Preferred Reporting Items for Systematic Review and Meta-Analysis Flow Diagram [15].
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2.2. Data sources and study eligibility
The literature conducted publications after 2000 in PubMed, ScienceDirect and Google
Scholar using keywords: “Economic Burden” OR “Non-Adherence Treatment” OR “TB”
AND “Indonesia.” Searches were not restricted by not using study design filters and
cross-referenced the citations from relevant systematic reviews and excerpts of recov-
ered articles. The literature searches screened in duplicate by using study eligibility
criteria.
2.3. Study inclusion criteria
Inclusion criteria of documents that consider appropriate to do systematic review were
as follows: a journal, an original study, and systematic analysis, reported in English and
Bahasa Indonesia, said the economic burden of TB treatment, and study location in
Indonesia.
2.4. Study exclusion criteria
Exclusion criteria were as follows: publication before the year 2000, magazines used a
language other than English and Bahasa Indonesia and purchased journals.
3. Results
This study identified seven eligible studies from Indonesia and resumed in conclusion
as shown in Table 1. Based on studies reviewed, for research design, the researcher
used cross-sectional and cohort. The studies showed there are factors affecting non-
adherence in TB, including economic status. TB treatment costs in all countries mostly
were much higher than diagnostic values. In Indonesia, right prices (out of pocket) for
treatment were more senior than indirect costs (foregone income) related to treatment.
The highest cost element in Indonesia during TB diagnosis was for transportation, food
supplements, laboratory tests and administration fees for MDR-TB patients [5].
Though most of TB diagnosis and treatment services are free, patients had other
direct and indirect costs and affected financially for most patients. MDR-TB patients
estimated costs for diagnosis and treatment were 3.4-13.9, higher than other TB patients
and MDR-TB patients more often lost their jobs.
Based onRutherford,M.E. et al. [6], self-employed (HR2.47, 95%CI 1.15-5.34) predicted
to treatment default than those in the highest income bracket. Patients with longer travel
time and higher travel costs not associated with an increased rate of default. Those who
paid >200.000 IDR (approx. 15 US$) were 0.24 (95%CI 0,06-0,91) times more likely to
default rather than those who spent>100.000-200.000 IDR and those who paid nothing.
The study revealed that TB poor patients in Central Java went directly to government
facilitieswhich diagnosis is free. Patientswhose eligible for government health insurance
were more likely to be adherent.
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Table 1: Journals in Review.
Title Author Year of
publish
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An Indonesian study [7] reported that productivity losses of US$12 per patient. Widja-
narko, B et al. [8] there are several factors that influence treatment adherence in Java,
Indonesia such as personal characteristics; costs and financial burden; knowledge,
beliefs, attitudes about TB; role of the traditional healer; community and household
support; stigma attached to tuberculosis; and health care service factors. Although TB
treatment in Indonesia is free, 30% of patients who live in rural areas had to pay much for
transportation to primary health care. Forty percent of non-adherent patients told that
costs played an important factor in deciding whether they adhered to the treatment.
The average income of non-adherent patients in private hospitals was three times lower
than the adherent patients, but this difference was less apparent in public hospitals.
Forty-nine studies in low-and-middle-income countries [9] revealed that the propor-
tion of direct medical costs out of total cost ranged from 0-62%, direct non-medical
prices ranged from 0-84% and indirect costs from 16-94% of total cost. Transportation
cost (range 11-96%) and food costs (range 0-89%) were the most significant cost that
contributes to direct non-medical expenses in 16 studies. The total cost for MDR-TB
patients was remarkably higher than drug-susceptible TB. Several studies revealed that
having TB had consequences for work and effects on adherence, TB treatment posed
an economic barrier because they often worked out of town, impact to their family
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livelihoods. Somepatients explained that TB treatment interruption by noting the costs of
treatment, such as hospitalized fee, Rontgen fee, and transport costs. Conflicts between
treatment, the hidden cost of treatment, and income could push patients into poverty and
this possibility as a reason for non-adherence treatment. In societies where depend on
family for financial support, poverty reported as a significant reason for non-adherence
treatment [10].
Productivity losses comprised 98% in low-and-middle-income countries [7]. In another
study on which most patients become unemployment in the most productive years of
their lives, the researcher found an unemployment rate about 57% and the families of
TB patients former had a lower median income than families without TB patients former
[11]. Because of this situation, their extended family bears the financial burden.
4. Discussion
In the studies reviewed, the financial impact was significant formost TB patients although
diagnosis and treatment services are supposed to be free on the other hand direct and
indirect cost increased while patients’ income was decreased [5,7-11]. Transport cost to
the clinic not associated with increased rates of non-adherence TB treatment in another
study [6]. Most TB patients referred to the closest clinic to their homes. TB is a giant
poverty producing mechanism and neglecting TB in one region will let poverty reign.
Besides, the relationship between disease and poverty like a vicious cycle. A sick person
is forced to have expensive clinical treatment and other fees that follow. As a result, the
poor became poorer and decided to stop the medication and get worse [4].
Economic loss caused by TB can be seen in four aspects [4], health consumption
effects is the loss in the form of decreased consumption of goods/health services due
to illness or death; social interaction and leisure effects is the disadvantage of social
interaction and lack of leisure time to relax; short term production effects, is medical
expenditure to get treated and loss of productive work days and the loss of opportunity
to take care of family properly; and long term production consumption effects can see
in the form of consumption demographical effects and workforce supply.
In line with those studies reviewed, a pilot study in Indonesia conducted by KNCV TB
Foundation [12] shows total approximated median patients costs for TB diagnosis and
treatment were around 1.5 million rupiahs. While total approximated median TB-MDR
patients’ prices were 15 times higher at about 22 million rupiahs. Patients told that TB
had affected their family financially, so they had different strategies to pay the expenses
during the diagnosis and treatment such as borrowingmoney and selling property/asset.
On the other hand, patients reported a lower income at the time of interview than before
the diagnosis of TB and the more significant drop in median household income occur
among MDR-TB patients. TB patients face a considerable financial impact due to their
treatment and become extraordinary to MDR-TB patients and family. A too high financial
burden may cause patients to default from treatment.
About 75% of TB cases arise during people’s most productive years between the ages
of 15 and 54, while people who are infected by TB are often unproductive and unable
to work which affected their family members [13]. The impact of TB usually measured as
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the direct costs of treatment to health services, which include the costs of medicines,
personnel, and facilities. While additional costs come from food required for TB patients
and the costs of travel to health services [14].
The total patient’s costs while seeking diagnosis and treatment include food, travel,
and accommodation would have been approximately US% 7.9 million. TB and MDR-TB
patients will lose their productivity due to the inability to be economically productive.
The study assumed that TB and MDR-TB treated patients are unable to work for 81 days
and 180 days after starting treatment due to illness and time spent to obtain daily care.
While, untreated TB and MDR-TB patients would be unable to work until they self-cure
or die, on average which is assumed to be three years. The total number of years of
life lost related to 2011 new cases are likely around 1.9 million and productive years of
experience failed to be 1.5 million. While the total economic burden will be roughly US$
2.1 billion and it will be higher each year related to the number of new TB cases [13].
Another study in Indonesia showed TB patients will lose 13 years of life and patients
who receive treatment are estimated to miss about two months’ work from illness and
untreated TB patients will lose about twelve months’ work. TB will cause psychological
and social costs; their circumstances may reject TB patients and lose their job. Besides,
discrimination for TB patients which can result in anxiety, depression, and reduce their
quality of life. High direct TB treatment costs for patients often take more than a month
before diagnosis made, extensive use of X-rays, prescription of expensive supplements,
and cooperation among providers [14].
The limitation of this systematic review is that only a few studies could about economic
burden/poverty that has an effect on non-adherence TB treatment in Indonesia and
just reviewed journal and research accessible on a database online with English and
Indonesian language. The content of discussion will be well if more publications about
the relationship between economic burden and non-adherence TB treatment. Another
possible limitation is that this systematic review only concludes the financial burden
affecting non-adherence TB treatment based on the conclusion of the research articles
and then qualitatively review of significance variables, without doing a meta-analysis to
combine the results of multiple scientific studies.
5. Conclusions
This systematic review found a consistent positive association between economic bur-
den and non-adherence TB treatment in Indonesia. The financial burden of TB patients
will affect patients’ productivity resulting in decreased income. The can be rough espe-
cially for TB patients who are the only one earner in the family. Also, long duration of
treatment may also result in TB patients not being able to work so that they may be dis-
missed or getting deduction payment by the employer. Costs incurred by patients such
as transportation costs, food expenses, and dietary supplements, and accommodation
costs during TB treatment are also determinants of non-adherence of TB treatment.
Thus, affordable health services including social protection schemes, are needed to
enable access, reduce delays and to compensate for the direct and indirect costs of
TB treatment.
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